Global Donafenib Tosylate Market Growth 2026-2032
The global Donafenib Tosylate market size is predicted to grow from US$ 34.63 million in 2025 to US$ 93.74 million in 2032; it is expected to grow at a CAGR of 6.2% from 2026 to 2032.
In 2025, global production of donafenib tosilate reached approximately 32,000 units.Donafenib Tosylate is an orally administered small-molecule multi-target tyrosine kinase inhibitor (TKI), primarily used for the treatment of malignant tumors such as hepatocellular carcinoma. It is the tosylate form of donafenib and exerts its effects by inhibiting multiple kinases associated with tumor growth and angiogenesis, including RAF kinases, VEGFR, and PDGFR, thereby blocking tumor cell proliferation and tumor angiogenesis.
Compared with traditional drugs of the same class, donafenib tosylate maintains antitumor activity while achieving improved safety and tolerability to a certain extent through structural optimization. As one of the domestically developed targeted anticancer drugs in China, it has been approved for first-line treatment of advanced hepatocellular carcinoma and demonstrates significant clinical value and promising development prospects.
Donafenib Tosylate, as a domestically developed small-molecule multi-target tyrosine kinase inhibitor in China, is primarily positioned in the hepatocellular carcinoma (HCC) treatment market. Globally, the incidence and mortality of liver cancer remain high, particularly in Asia-Pacific regions such as China, where the large patient population provides a stable and continuously growing market demand for this drug. From a competitive perspective, targeted therapies such as sorafenib and lenvatinib have already captured a certain market share; however, with increasing clinical demands for improved efficacy and safety, next-generation drugs are gaining attention. Clinical studies have demonstrated that donafenib tosylate offers favorable survival benefits and tolerability, giving it a competitive advantage in the first-line treatment setting.
In the Chinese market, government support for innovative drugs, improvements in reimbursement access, and the implementation of centralized procurement policies are expected to enhance drug accessibility and promote market penetration. Meanwhile, with the advancement of precision medicine and the continuous standardization of clinical treatment practices, targeted therapies with differentiated advantages are more likely to gain acceptance among physicians and patients. From a global perspective, the demand for targeted cancer therapies continues to grow; however, entry into mature markets such as Europe and the United States will still require further clinical evidence and regulatory approvals.
LP Information, Inc. (LPI) ' newest research report, the ?Donafenib Tosylate Industry Forecast? looks at past sales and reviews total world Donafenib Tosylate sales in 2025, providing a comprehensive analysis by region and market sector of projected Donafenib Tosylate sales for 2026 through 2032. With Donafenib Tosylate sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Donafenib Tosylate industry.
This Insight Report provides a comprehensive analysis of the global Donafenib Tosylate landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Donafenib Tosylate portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Donafenib Tosylate market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Donafenib Tosylate and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Donafenib Tosylate.
This report presents a comprehensive overview, market shares, and growth opportunities of Donafenib Tosylate market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Donafenib Tosylate market?
What factors are driving Donafenib Tosylate market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Donafenib Tosylate market opportunities vary by end market size?
How does Donafenib Tosylate break out by Type, by Application?
In 2025, global production of donafenib tosilate reached approximately 32,000 units.Donafenib Tosylate is an orally administered small-molecule multi-target tyrosine kinase inhibitor (TKI), primarily used for the treatment of malignant tumors such as hepatocellular carcinoma. It is the tosylate form of donafenib and exerts its effects by inhibiting multiple kinases associated with tumor growth and angiogenesis, including RAF kinases, VEGFR, and PDGFR, thereby blocking tumor cell proliferation and tumor angiogenesis.
Compared with traditional drugs of the same class, donafenib tosylate maintains antitumor activity while achieving improved safety and tolerability to a certain extent through structural optimization. As one of the domestically developed targeted anticancer drugs in China, it has been approved for first-line treatment of advanced hepatocellular carcinoma and demonstrates significant clinical value and promising development prospects.
Donafenib Tosylate, as a domestically developed small-molecule multi-target tyrosine kinase inhibitor in China, is primarily positioned in the hepatocellular carcinoma (HCC) treatment market. Globally, the incidence and mortality of liver cancer remain high, particularly in Asia-Pacific regions such as China, where the large patient population provides a stable and continuously growing market demand for this drug. From a competitive perspective, targeted therapies such as sorafenib and lenvatinib have already captured a certain market share; however, with increasing clinical demands for improved efficacy and safety, next-generation drugs are gaining attention. Clinical studies have demonstrated that donafenib tosylate offers favorable survival benefits and tolerability, giving it a competitive advantage in the first-line treatment setting.
In the Chinese market, government support for innovative drugs, improvements in reimbursement access, and the implementation of centralized procurement policies are expected to enhance drug accessibility and promote market penetration. Meanwhile, with the advancement of precision medicine and the continuous standardization of clinical treatment practices, targeted therapies with differentiated advantages are more likely to gain acceptance among physicians and patients. From a global perspective, the demand for targeted cancer therapies continues to grow; however, entry into mature markets such as Europe and the United States will still require further clinical evidence and regulatory approvals.
LP Information, Inc. (LPI) ' newest research report, the ?Donafenib Tosylate Industry Forecast? looks at past sales and reviews total world Donafenib Tosylate sales in 2025, providing a comprehensive analysis by region and market sector of projected Donafenib Tosylate sales for 2026 through 2032. With Donafenib Tosylate sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Donafenib Tosylate industry.
This Insight Report provides a comprehensive analysis of the global Donafenib Tosylate landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Donafenib Tosylate portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Donafenib Tosylate market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Donafenib Tosylate and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Donafenib Tosylate.
This report presents a comprehensive overview, market shares, and growth opportunities of Donafenib Tosylate market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 200 mg
- 300 mg
- Hospital
- Retail
- Online
- Tablets
- Powder
- Hepatocellular Carcinoma (HCC)
- Inhibit tumor Cell Proliferation
- Inhibit tumor Angiogenesis
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Suzhou Zelgen Biopharmaceuticals
- Zhejiang Apeloa Kangyu Pharmaceutical
What is the 10-year outlook for the global Donafenib Tosylate market?
What factors are driving Donafenib Tosylate market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Donafenib Tosylate market opportunities vary by end market size?
How does Donafenib Tosylate break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Donafenib Tosylate Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Donafenib Tosylate by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Donafenib Tosylate by Country/Region, 2021, 2025 & 2032
2.2 Donafenib Tosylate Segment by Type
2.2.1 200 mg
2.2.2 300 mg
2.2.3 Donafenib Tosylate Sales by Type
2.2.3.1 Global Donafenib Tosylate Sales Market Share by Type (2021-2026)
2.2.3.2 Global Donafenib Tosylate Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Donafenib Tosylate Sale Price by Type (2021-2026)
2.3 Donafenib Tosylate Segment by Sales Channels
2.3.1 Hospital
2.3.2 Retail
2.3.3 Online
2.3.4 Donafenib Tosylate Sales by Sales Channels
2.3.4.1 Global Donafenib Tosylate Sales Market Share by Sales Channels (2021-2026)
2.3.4.2 Global Donafenib Tosylate Revenue and Market Share by Sales Channels (2021-2026)
2.3.4.3 Global Donafenib Tosylate Sale Price by Sales Channels (2021-2026)
2.4 Donafenib Tosylate Segment by Dosage Form
2.4.1 Tablets
2.4.2 Powder
2.4.3 Donafenib Tosylate Sales by Dosage Form
2.4.3.1 Global Donafenib Tosylate Sales Market Share by Dosage Form (2021-2026)
2.4.3.2 Global Donafenib Tosylate Revenue and Market Share by Dosage Form (2021-2026)
2.4.3.3 Global Donafenib Tosylate Sale Price by Dosage Form (2021-2026)
2.5 Donafenib Tosylate Segment by Application
2.5.1 Hepatocellular Carcinoma (HCC)
2.5.2 Inhibit tumor Cell Proliferation
2.5.3 Inhibit tumor Angiogenesis
2.5.4 Others
2.5.5 Donafenib Tosylate Sales by Application
2.5.5.1 Global Donafenib Tosylate Sale Market Share by Application (2021-2026)
2.5.5.2 Global Donafenib Tosylate Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Donafenib Tosylate Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Donafenib Tosylate Breakdown Data by Company
3.1.1 Global Donafenib Tosylate Annual Sales by Company (2021-2026)
3.1.2 Global Donafenib Tosylate Sales Market Share by Company (2021-2026)
3.2 Global Donafenib Tosylate Annual Revenue by Company (2021-2026)
3.2.1 Global Donafenib Tosylate Revenue by Company (2021-2026)
3.2.2 Global Donafenib Tosylate Revenue Market Share by Company (2021-2026)
3.3 Global Donafenib Tosylate Sale Price by Company
3.4 Key Manufacturers Donafenib Tosylate Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Donafenib Tosylate Product Location Distribution
3.4.2 Players Donafenib Tosylate Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DONAFENIB TOSYLATE BY GEOGRAPHIC REGION
4.1 World Historic Donafenib Tosylate Market Size by Geographic Region (2021-2026)
4.1.1 Global Donafenib Tosylate Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Donafenib Tosylate Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Donafenib Tosylate Market Size by Country/Region (2021-2026)
4.2.1 Global Donafenib Tosylate Annual Sales by Country/Region (2021-2026)
4.2.2 Global Donafenib Tosylate Annual Revenue by Country/Region (2021-2026)
4.3 Americas Donafenib Tosylate Sales Growth
4.4 APAC Donafenib Tosylate Sales Growth
4.5 Europe Donafenib Tosylate Sales Growth
4.6 Middle East & Africa Donafenib Tosylate Sales Growth
5 AMERICAS
5.1 Americas Donafenib Tosylate Sales by Country
5.1.1 Americas Donafenib Tosylate Sales by Country (2021-2026)
5.1.2 Americas Donafenib Tosylate Revenue by Country (2021-2026)
5.2 Americas Donafenib Tosylate Sales by Type (2021-2026)
5.3 Americas Donafenib Tosylate Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Donafenib Tosylate Sales by Region
6.1.1 APAC Donafenib Tosylate Sales by Region (2021-2026)
6.1.2 APAC Donafenib Tosylate Revenue by Region (2021-2026)
6.2 APAC Donafenib Tosylate Sales by Type (2021-2026)
6.3 APAC Donafenib Tosylate Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Donafenib Tosylate by Country
7.1.1 Europe Donafenib Tosylate Sales by Country (2021-2026)
7.1.2 Europe Donafenib Tosylate Revenue by Country (2021-2026)
7.2 Europe Donafenib Tosylate Sales by Type (2021-2026)
7.3 Europe Donafenib Tosylate Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Donafenib Tosylate by Country
8.1.1 Middle East & Africa Donafenib Tosylate Sales by Country (2021-2026)
8.1.2 Middle East & Africa Donafenib Tosylate Revenue by Country (2021-2026)
8.2 Middle East & Africa Donafenib Tosylate Sales by Type (2021-2026)
8.3 Middle East & Africa Donafenib Tosylate Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Donafenib Tosylate
10.3 Manufacturing Process Analysis of Donafenib Tosylate
10.4 Industry Chain Structure of Donafenib Tosylate
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Donafenib Tosylate Distributors
11.3 Donafenib Tosylate Customer
12 WORLD FORECAST REVIEW FOR DONAFENIB TOSYLATE BY GEOGRAPHIC REGION
12.1 Global Donafenib Tosylate Market Size Forecast by Region
12.1.1 Global Donafenib Tosylate Forecast by Region (2027-2032)
12.1.2 Global Donafenib Tosylate Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Donafenib Tosylate Forecast by Type (2027-2032)
12.7 Global Donafenib Tosylate Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Suzhou Zelgen Biopharmaceuticals
13.1.1 Suzhou Zelgen Biopharmaceuticals Company Information
13.1.2 Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Product Portfolios and Specifications
13.1.3 Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview
13.1.5 Suzhou Zelgen Biopharmaceuticals Latest Developments
13.2 Zhejiang Apeloa Kangyu Pharmaceutical
13.2.1 Zhejiang Apeloa Kangyu Pharmaceutical Company Information
13.2.2 Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Product Portfolios and Specifications
13.2.3 Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Zhejiang Apeloa Kangyu Pharmaceutical Main Business Overview
13.2.5 Zhejiang Apeloa Kangyu Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Donafenib Tosylate Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Donafenib Tosylate by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Donafenib Tosylate by Country/Region, 2021, 2025 & 2032
2.2 Donafenib Tosylate Segment by Type
2.2.1 200 mg
2.2.2 300 mg
2.2.3 Donafenib Tosylate Sales by Type
2.2.3.1 Global Donafenib Tosylate Sales Market Share by Type (2021-2026)
2.2.3.2 Global Donafenib Tosylate Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Donafenib Tosylate Sale Price by Type (2021-2026)
2.3 Donafenib Tosylate Segment by Sales Channels
2.3.1 Hospital
2.3.2 Retail
2.3.3 Online
2.3.4 Donafenib Tosylate Sales by Sales Channels
2.3.4.1 Global Donafenib Tosylate Sales Market Share by Sales Channels (2021-2026)
2.3.4.2 Global Donafenib Tosylate Revenue and Market Share by Sales Channels (2021-2026)
2.3.4.3 Global Donafenib Tosylate Sale Price by Sales Channels (2021-2026)
2.4 Donafenib Tosylate Segment by Dosage Form
2.4.1 Tablets
2.4.2 Powder
2.4.3 Donafenib Tosylate Sales by Dosage Form
2.4.3.1 Global Donafenib Tosylate Sales Market Share by Dosage Form (2021-2026)
2.4.3.2 Global Donafenib Tosylate Revenue and Market Share by Dosage Form (2021-2026)
2.4.3.3 Global Donafenib Tosylate Sale Price by Dosage Form (2021-2026)
2.5 Donafenib Tosylate Segment by Application
2.5.1 Hepatocellular Carcinoma (HCC)
2.5.2 Inhibit tumor Cell Proliferation
2.5.3 Inhibit tumor Angiogenesis
2.5.4 Others
2.5.5 Donafenib Tosylate Sales by Application
2.5.5.1 Global Donafenib Tosylate Sale Market Share by Application (2021-2026)
2.5.5.2 Global Donafenib Tosylate Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Donafenib Tosylate Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Donafenib Tosylate Breakdown Data by Company
3.1.1 Global Donafenib Tosylate Annual Sales by Company (2021-2026)
3.1.2 Global Donafenib Tosylate Sales Market Share by Company (2021-2026)
3.2 Global Donafenib Tosylate Annual Revenue by Company (2021-2026)
3.2.1 Global Donafenib Tosylate Revenue by Company (2021-2026)
3.2.2 Global Donafenib Tosylate Revenue Market Share by Company (2021-2026)
3.3 Global Donafenib Tosylate Sale Price by Company
3.4 Key Manufacturers Donafenib Tosylate Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Donafenib Tosylate Product Location Distribution
3.4.2 Players Donafenib Tosylate Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DONAFENIB TOSYLATE BY GEOGRAPHIC REGION
4.1 World Historic Donafenib Tosylate Market Size by Geographic Region (2021-2026)
4.1.1 Global Donafenib Tosylate Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Donafenib Tosylate Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Donafenib Tosylate Market Size by Country/Region (2021-2026)
4.2.1 Global Donafenib Tosylate Annual Sales by Country/Region (2021-2026)
4.2.2 Global Donafenib Tosylate Annual Revenue by Country/Region (2021-2026)
4.3 Americas Donafenib Tosylate Sales Growth
4.4 APAC Donafenib Tosylate Sales Growth
4.5 Europe Donafenib Tosylate Sales Growth
4.6 Middle East & Africa Donafenib Tosylate Sales Growth
5 AMERICAS
5.1 Americas Donafenib Tosylate Sales by Country
5.1.1 Americas Donafenib Tosylate Sales by Country (2021-2026)
5.1.2 Americas Donafenib Tosylate Revenue by Country (2021-2026)
5.2 Americas Donafenib Tosylate Sales by Type (2021-2026)
5.3 Americas Donafenib Tosylate Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Donafenib Tosylate Sales by Region
6.1.1 APAC Donafenib Tosylate Sales by Region (2021-2026)
6.1.2 APAC Donafenib Tosylate Revenue by Region (2021-2026)
6.2 APAC Donafenib Tosylate Sales by Type (2021-2026)
6.3 APAC Donafenib Tosylate Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Donafenib Tosylate by Country
7.1.1 Europe Donafenib Tosylate Sales by Country (2021-2026)
7.1.2 Europe Donafenib Tosylate Revenue by Country (2021-2026)
7.2 Europe Donafenib Tosylate Sales by Type (2021-2026)
7.3 Europe Donafenib Tosylate Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Donafenib Tosylate by Country
8.1.1 Middle East & Africa Donafenib Tosylate Sales by Country (2021-2026)
8.1.2 Middle East & Africa Donafenib Tosylate Revenue by Country (2021-2026)
8.2 Middle East & Africa Donafenib Tosylate Sales by Type (2021-2026)
8.3 Middle East & Africa Donafenib Tosylate Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Donafenib Tosylate
10.3 Manufacturing Process Analysis of Donafenib Tosylate
10.4 Industry Chain Structure of Donafenib Tosylate
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Donafenib Tosylate Distributors
11.3 Donafenib Tosylate Customer
12 WORLD FORECAST REVIEW FOR DONAFENIB TOSYLATE BY GEOGRAPHIC REGION
12.1 Global Donafenib Tosylate Market Size Forecast by Region
12.1.1 Global Donafenib Tosylate Forecast by Region (2027-2032)
12.1.2 Global Donafenib Tosylate Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Donafenib Tosylate Forecast by Type (2027-2032)
12.7 Global Donafenib Tosylate Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Suzhou Zelgen Biopharmaceuticals
13.1.1 Suzhou Zelgen Biopharmaceuticals Company Information
13.1.2 Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Product Portfolios and Specifications
13.1.3 Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview
13.1.5 Suzhou Zelgen Biopharmaceuticals Latest Developments
13.2 Zhejiang Apeloa Kangyu Pharmaceutical
13.2.1 Zhejiang Apeloa Kangyu Pharmaceutical Company Information
13.2.2 Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Product Portfolios and Specifications
13.2.3 Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Zhejiang Apeloa Kangyu Pharmaceutical Main Business Overview
13.2.5 Zhejiang Apeloa Kangyu Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Donafenib Tosylate Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Donafenib Tosylate Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 200 mg
Table 4. Major Players of 300 mg
Table 5. Global Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 6. Global Donafenib Tosylate Sales Market Share by Type (2021-2026)
Table 7. Global Donafenib Tosylate Revenue by Type (2021-2026) & ($ million)
Table 8. Global Donafenib Tosylate Revenue Market Share by Type (2021-2026)
Table 9. Global Donafenib Tosylate Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Hospital
Table 11. Major Players of Retail
Table 12. Major Players of Online
Table 13. Global Donafenib Tosylate Sales by Sales Channels (2021-2026) & (Units)
Table 14. Global Donafenib Tosylate Sales Market Share by Sales Channels (2021-2026)
Table 15. Global Donafenib Tosylate Revenue by Sales Channels (2021-2026) & ($ million)
Table 16. Global Donafenib Tosylate Revenue Market Share by Sales Channels (2021-2026)
Table 17. Global Donafenib Tosylate Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 18. Major Players ofTablets
Table 19. Major Players of Powder
Table 20. Global Donafenib Tosylate Sales by Dosage Form (2021-2026) & (Units)
Table 21. Global Donafenib Tosylate Sales Market Share by Dosage Form (2021-2026)
Table 22. Global Donafenib Tosylate Revenue by Dosage Form (2021-2026) & ($ million)
Table 23. Global Donafenib Tosylate Revenue Market Share by Dosage Form (2021-2026)
Table 24. Global Donafenib Tosylate Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 25. Global Donafenib Tosylate Sale by Application (2021-2026) & (Units)
Table 26. Global Donafenib Tosylate Sale Market Share by Application (2021-2026)
Table 27. Global Donafenib Tosylate Revenue by Application (2021-2026) & ($ million)
Table 28. Global Donafenib Tosylate Revenue Market Share by Application (2021-2026)
Table 29. Global Donafenib Tosylate Sale Price by Application (2021-2026) & (US$/Unit)
Table 30. Global Donafenib Tosylate Sales by Company (2021-2026) & (Units)
Table 31. Global Donafenib Tosylate Sales Market Share by Company (2021-2026)
Table 32. Global Donafenib Tosylate Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Donafenib Tosylate Revenue Market Share by Company (2021-2026)
Table 34. Global Donafenib Tosylate Sale Price by Company (2021-2026) & (US$/Unit)
Table 35. Key Manufacturers Donafenib Tosylate Producing Area Distribution and Sales Area
Table 36. Players Donafenib Tosylate Products Offered
Table 37. Donafenib Tosylate Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Donafenib Tosylate Sales by Geographic Region (2021-2026) & (Units)
Table 41. Global Donafenib Tosylate Sales Market Share Geographic Region (2021-2026)
Table 42. Global Donafenib Tosylate Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Donafenib Tosylate Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Donafenib Tosylate Sales by Country/Region (2021-2026) & (Units)
Table 45. Global Donafenib Tosylate Sales Market Share by Country/Region (2021-2026)
Table 46. Global Donafenib Tosylate Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Donafenib Tosylate Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Donafenib Tosylate Sales by Country (2021-2026) & (Units)
Table 49. Americas Donafenib Tosylate Sales Market Share by Country (2021-2026)
Table 50. Americas Donafenib Tosylate Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 52. Americas Donafenib Tosylate Sales by Application (2021-2026) & (Units)
Table 53. APAC Donafenib Tosylate Sales by Region (2021-2026) & (Units)
Table 54. APAC Donafenib Tosylate Sales Market Share by Region (2021-2026)
Table 55. APAC Donafenib Tosylate Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 57. APAC Donafenib Tosylate Sales by Application (2021-2026) & (Units)
Table 58. Europe Donafenib Tosylate Sales by Country (2021-2026) & (Units)
Table 59. Europe Donafenib Tosylate Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 61. Europe Donafenib Tosylate Sales by Application (2021-2026) & (Units)
Table 62. Middle East & Africa Donafenib Tosylate Sales by Country (2021-2026) & (Units)
Table 63. Middle East & Africa Donafenib Tosylate Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 65. Middle East & Africa Donafenib Tosylate Sales by Application (2021-2026) & (Units)
Table 66. Key Market Drivers & Growth Opportunities of Donafenib Tosylate
Table 67. Key Market Challenges & Risks of Donafenib Tosylate
Table 68. Key Industry Trends of Donafenib Tosylate
Table 69. Donafenib Tosylate Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Donafenib Tosylate Distributors List
Table 72. Donafenib Tosylate Customer List
Table 73. Global Donafenib Tosylate Sales Forecast by Region (2027-2032) & (Units)
Table 74. Global Donafenib Tosylate Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Donafenib Tosylate Sales Forecast by Country (2027-2032) & (Units)
Table 76. Americas Donafenib Tosylate Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Donafenib Tosylate Sales Forecast by Region (2027-2032) & (Units)
Table 78. APAC Donafenib Tosylate Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Donafenib Tosylate Sales Forecast by Country (2027-2032) & (Units)
Table 80. Europe Donafenib Tosylate Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Donafenib Tosylate Sales Forecast by Country (2027-2032) & (Units)
Table 82. Middle East & Africa Donafenib Tosylate Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Donafenib Tosylate Sales Forecast by Type (2027-2032) & (Units)
Table 84. Global Donafenib Tosylate Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Donafenib Tosylate Sales Forecast by Application (2027-2032) & (Units)
Table 86. Global Donafenib Tosylate Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Suzhou Zelgen Biopharmaceuticals Basic Information, Donafenib Tosylate Manufacturing Base, Sales Area and Its Competitors
Table 88. Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Product Portfolios and Specifications
Table 89. Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Suzhou Zelgen Biopharmaceuticals Main Business
Table 91. Suzhou Zelgen Biopharmaceuticals Latest Developments
Table 92. Zhejiang Apeloa Kangyu Pharmaceutical Basic Information, Donafenib Tosylate Manufacturing Base, Sales Area and Its Competitors
Table 93. Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Product Portfolios and Specifications
Table 94. Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Zhejiang Apeloa Kangyu Pharmaceutical Main Business
Table 96. Zhejiang Apeloa Kangyu Pharmaceutical Latest Developments
Table 1. Donafenib Tosylate Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Donafenib Tosylate Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 200 mg
Table 4. Major Players of 300 mg
Table 5. Global Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 6. Global Donafenib Tosylate Sales Market Share by Type (2021-2026)
Table 7. Global Donafenib Tosylate Revenue by Type (2021-2026) & ($ million)
Table 8. Global Donafenib Tosylate Revenue Market Share by Type (2021-2026)
Table 9. Global Donafenib Tosylate Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Hospital
Table 11. Major Players of Retail
Table 12. Major Players of Online
Table 13. Global Donafenib Tosylate Sales by Sales Channels (2021-2026) & (Units)
Table 14. Global Donafenib Tosylate Sales Market Share by Sales Channels (2021-2026)
Table 15. Global Donafenib Tosylate Revenue by Sales Channels (2021-2026) & ($ million)
Table 16. Global Donafenib Tosylate Revenue Market Share by Sales Channels (2021-2026)
Table 17. Global Donafenib Tosylate Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 18. Major Players ofTablets
Table 19. Major Players of Powder
Table 20. Global Donafenib Tosylate Sales by Dosage Form (2021-2026) & (Units)
Table 21. Global Donafenib Tosylate Sales Market Share by Dosage Form (2021-2026)
Table 22. Global Donafenib Tosylate Revenue by Dosage Form (2021-2026) & ($ million)
Table 23. Global Donafenib Tosylate Revenue Market Share by Dosage Form (2021-2026)
Table 24. Global Donafenib Tosylate Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 25. Global Donafenib Tosylate Sale by Application (2021-2026) & (Units)
Table 26. Global Donafenib Tosylate Sale Market Share by Application (2021-2026)
Table 27. Global Donafenib Tosylate Revenue by Application (2021-2026) & ($ million)
Table 28. Global Donafenib Tosylate Revenue Market Share by Application (2021-2026)
Table 29. Global Donafenib Tosylate Sale Price by Application (2021-2026) & (US$/Unit)
Table 30. Global Donafenib Tosylate Sales by Company (2021-2026) & (Units)
Table 31. Global Donafenib Tosylate Sales Market Share by Company (2021-2026)
Table 32. Global Donafenib Tosylate Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Donafenib Tosylate Revenue Market Share by Company (2021-2026)
Table 34. Global Donafenib Tosylate Sale Price by Company (2021-2026) & (US$/Unit)
Table 35. Key Manufacturers Donafenib Tosylate Producing Area Distribution and Sales Area
Table 36. Players Donafenib Tosylate Products Offered
Table 37. Donafenib Tosylate Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Donafenib Tosylate Sales by Geographic Region (2021-2026) & (Units)
Table 41. Global Donafenib Tosylate Sales Market Share Geographic Region (2021-2026)
Table 42. Global Donafenib Tosylate Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Donafenib Tosylate Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Donafenib Tosylate Sales by Country/Region (2021-2026) & (Units)
Table 45. Global Donafenib Tosylate Sales Market Share by Country/Region (2021-2026)
Table 46. Global Donafenib Tosylate Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Donafenib Tosylate Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Donafenib Tosylate Sales by Country (2021-2026) & (Units)
Table 49. Americas Donafenib Tosylate Sales Market Share by Country (2021-2026)
Table 50. Americas Donafenib Tosylate Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 52. Americas Donafenib Tosylate Sales by Application (2021-2026) & (Units)
Table 53. APAC Donafenib Tosylate Sales by Region (2021-2026) & (Units)
Table 54. APAC Donafenib Tosylate Sales Market Share by Region (2021-2026)
Table 55. APAC Donafenib Tosylate Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 57. APAC Donafenib Tosylate Sales by Application (2021-2026) & (Units)
Table 58. Europe Donafenib Tosylate Sales by Country (2021-2026) & (Units)
Table 59. Europe Donafenib Tosylate Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 61. Europe Donafenib Tosylate Sales by Application (2021-2026) & (Units)
Table 62. Middle East & Africa Donafenib Tosylate Sales by Country (2021-2026) & (Units)
Table 63. Middle East & Africa Donafenib Tosylate Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Donafenib Tosylate Sales by Type (2021-2026) & (Units)
Table 65. Middle East & Africa Donafenib Tosylate Sales by Application (2021-2026) & (Units)
Table 66. Key Market Drivers & Growth Opportunities of Donafenib Tosylate
Table 67. Key Market Challenges & Risks of Donafenib Tosylate
Table 68. Key Industry Trends of Donafenib Tosylate
Table 69. Donafenib Tosylate Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Donafenib Tosylate Distributors List
Table 72. Donafenib Tosylate Customer List
Table 73. Global Donafenib Tosylate Sales Forecast by Region (2027-2032) & (Units)
Table 74. Global Donafenib Tosylate Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Donafenib Tosylate Sales Forecast by Country (2027-2032) & (Units)
Table 76. Americas Donafenib Tosylate Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Donafenib Tosylate Sales Forecast by Region (2027-2032) & (Units)
Table 78. APAC Donafenib Tosylate Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Donafenib Tosylate Sales Forecast by Country (2027-2032) & (Units)
Table 80. Europe Donafenib Tosylate Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Donafenib Tosylate Sales Forecast by Country (2027-2032) & (Units)
Table 82. Middle East & Africa Donafenib Tosylate Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Donafenib Tosylate Sales Forecast by Type (2027-2032) & (Units)
Table 84. Global Donafenib Tosylate Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Donafenib Tosylate Sales Forecast by Application (2027-2032) & (Units)
Table 86. Global Donafenib Tosylate Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Suzhou Zelgen Biopharmaceuticals Basic Information, Donafenib Tosylate Manufacturing Base, Sales Area and Its Competitors
Table 88. Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Product Portfolios and Specifications
Table 89. Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Suzhou Zelgen Biopharmaceuticals Main Business
Table 91. Suzhou Zelgen Biopharmaceuticals Latest Developments
Table 92. Zhejiang Apeloa Kangyu Pharmaceutical Basic Information, Donafenib Tosylate Manufacturing Base, Sales Area and Its Competitors
Table 93. Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Product Portfolios and Specifications
Table 94. Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Zhejiang Apeloa Kangyu Pharmaceutical Main Business
Table 96. Zhejiang Apeloa Kangyu Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Donafenib Tosylate
Figure 2. Donafenib Tosylate Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Donafenib Tosylate Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Donafenib Tosylate Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Donafenib Tosylate Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Donafenib Tosylate Sales Market Share by Country/Region (2025)
Figure 10. Donafenib Tosylate Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 200 mg
Figure 12. Product Picture of 300 mg
Figure 13. Global Donafenib Tosylate Sales Market Share by Type in 2026
Figure 14. Global Donafenib Tosylate Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Hospital
Figure 16. Product Picture of Retail
Figure 17. Product Picture of Online
Figure 18. Global Donafenib Tosylate Sales Market Share by Sales Channels in 2026
Figure 19. Global Donafenib Tosylate Revenue Market Share by Sales Channels (2021-2026)
Figure 20. Product Picture ofTablets
Figure 21. Product Picture of Powder
Figure 22. Global Donafenib Tosylate Sales Market Share by Dosage Form in 2026
Figure 23. Global Donafenib Tosylate Revenue Market Share by Dosage Form (2021-2026)
Figure 24. Donafenib Tosylate Consumed in Hepatocellular Carcinoma (HCC)
Figure 25. Global Donafenib Tosylate Market: Hepatocellular Carcinoma (HCC) (2021-2026) & (Units)
Figure 26. Donafenib Tosylate Consumed in Inhibit tumor Cell Proliferation
Figure 27. Global Donafenib Tosylate Market: Inhibit tumor Cell Proliferation (2021-2026) & (Units)
Figure 28. Donafenib Tosylate Consumed in Inhibit tumor Angiogenesis
Figure 29. Global Donafenib Tosylate Market: Inhibit tumor Angiogenesis (2021-2026) & (Units)
Figure 30. Donafenib Tosylate Consumed in Others
Figure 31. Global Donafenib Tosylate Market: Others (2021-2026) & (Units)
Figure 32. Global Donafenib Tosylate Sale Market Share by Application (2025)
Figure 33. Global Donafenib Tosylate Revenue Market Share by Application in 2025
Figure 34. Donafenib Tosylate Sales by Company in 2025 (Units)
Figure 35. Global Donafenib Tosylate Sales Market Share by Company in 2025
Figure 36. Donafenib Tosylate Revenue by Company in 2025 ($ millions)
Figure 37. Global Donafenib Tosylate Revenue Market Share by Company in 2025
Figure 38. Global Donafenib Tosylate Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Donafenib Tosylate Revenue Market Share by Geographic Region in 2025
Figure 40. Americas Donafenib Tosylate Sales 2021-2026 (Units)
Figure 41. Americas Donafenib Tosylate Revenue 2021-2026 ($ millions)
Figure 42. APAC Donafenib Tosylate Sales 2021-2026 (Units)
Figure 43. APAC Donafenib Tosylate Revenue 2021-2026 ($ millions)
Figure 44. Europe Donafenib Tosylate Sales 2021-2026 (Units)
Figure 45. Europe Donafenib Tosylate Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Donafenib Tosylate Sales 2021-2026 (Units)
Figure 47. Middle East & Africa Donafenib Tosylate Revenue 2021-2026 ($ millions)
Figure 48. Americas Donafenib Tosylate Sales Market Share by Country in 2025
Figure 49. Americas Donafenib Tosylate Revenue Market Share by Country (2021-2026)
Figure 50. Americas Donafenib Tosylate Sales Market Share by Type (2021-2026)
Figure 51. Americas Donafenib Tosylate Sales Market Share by Application (2021-2026)
Figure 52. United States Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Donafenib Tosylate Sales Market Share by Region in 2025
Figure 57. APAC Donafenib Tosylate Revenue Market Share by Region (2021-2026)
Figure 58. APAC Donafenib Tosylate Sales Market Share by Type (2021-2026)
Figure 59. APAC Donafenib Tosylate Sales Market Share by Application (2021-2026)
Figure 60. China Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 64. India Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Donafenib Tosylate Sales Market Share by Country in 2025
Figure 68. Europe Donafenib Tosylate Revenue Market Share by Country (2021-2026)
Figure 69. Europe Donafenib Tosylate Sales Market Share by Type (2021-2026)
Figure 70. Europe Donafenib Tosylate Sales Market Share by Application (2021-2026)
Figure 71. Germany Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 72. France Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Donafenib Tosylate Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Donafenib Tosylate Sales Market Share by Type (2021-2026)
Figure 78. Middle East & Africa Donafenib Tosylate Sales Market Share by Application (2021-2026)
Figure 79. Egypt Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Donafenib Tosylate in 2026
Figure 85. Manufacturing Process Analysis of Donafenib Tosylate
Figure 86. Industry Chain Structure of Donafenib Tosylate
Figure 87. Channels of Distribution
Figure 88. Global Donafenib Tosylate Sales Market Forecast by Region (2027-2032)
Figure 89. Global Donafenib Tosylate Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Donafenib Tosylate Sales Market Share Forecast by Type (2027-2032)
Figure 91. Global Donafenib Tosylate Revenue Market Share Forecast by Type (2027-2032)
Figure 92. Global Donafenib Tosylate Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Donafenib Tosylate Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Donafenib Tosylate
Figure 2. Donafenib Tosylate Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Donafenib Tosylate Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Donafenib Tosylate Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Donafenib Tosylate Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Donafenib Tosylate Sales Market Share by Country/Region (2025)
Figure 10. Donafenib Tosylate Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 200 mg
Figure 12. Product Picture of 300 mg
Figure 13. Global Donafenib Tosylate Sales Market Share by Type in 2026
Figure 14. Global Donafenib Tosylate Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Hospital
Figure 16. Product Picture of Retail
Figure 17. Product Picture of Online
Figure 18. Global Donafenib Tosylate Sales Market Share by Sales Channels in 2026
Figure 19. Global Donafenib Tosylate Revenue Market Share by Sales Channels (2021-2026)
Figure 20. Product Picture ofTablets
Figure 21. Product Picture of Powder
Figure 22. Global Donafenib Tosylate Sales Market Share by Dosage Form in 2026
Figure 23. Global Donafenib Tosylate Revenue Market Share by Dosage Form (2021-2026)
Figure 24. Donafenib Tosylate Consumed in Hepatocellular Carcinoma (HCC)
Figure 25. Global Donafenib Tosylate Market: Hepatocellular Carcinoma (HCC) (2021-2026) & (Units)
Figure 26. Donafenib Tosylate Consumed in Inhibit tumor Cell Proliferation
Figure 27. Global Donafenib Tosylate Market: Inhibit tumor Cell Proliferation (2021-2026) & (Units)
Figure 28. Donafenib Tosylate Consumed in Inhibit tumor Angiogenesis
Figure 29. Global Donafenib Tosylate Market: Inhibit tumor Angiogenesis (2021-2026) & (Units)
Figure 30. Donafenib Tosylate Consumed in Others
Figure 31. Global Donafenib Tosylate Market: Others (2021-2026) & (Units)
Figure 32. Global Donafenib Tosylate Sale Market Share by Application (2025)
Figure 33. Global Donafenib Tosylate Revenue Market Share by Application in 2025
Figure 34. Donafenib Tosylate Sales by Company in 2025 (Units)
Figure 35. Global Donafenib Tosylate Sales Market Share by Company in 2025
Figure 36. Donafenib Tosylate Revenue by Company in 2025 ($ millions)
Figure 37. Global Donafenib Tosylate Revenue Market Share by Company in 2025
Figure 38. Global Donafenib Tosylate Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Donafenib Tosylate Revenue Market Share by Geographic Region in 2025
Figure 40. Americas Donafenib Tosylate Sales 2021-2026 (Units)
Figure 41. Americas Donafenib Tosylate Revenue 2021-2026 ($ millions)
Figure 42. APAC Donafenib Tosylate Sales 2021-2026 (Units)
Figure 43. APAC Donafenib Tosylate Revenue 2021-2026 ($ millions)
Figure 44. Europe Donafenib Tosylate Sales 2021-2026 (Units)
Figure 45. Europe Donafenib Tosylate Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Donafenib Tosylate Sales 2021-2026 (Units)
Figure 47. Middle East & Africa Donafenib Tosylate Revenue 2021-2026 ($ millions)
Figure 48. Americas Donafenib Tosylate Sales Market Share by Country in 2025
Figure 49. Americas Donafenib Tosylate Revenue Market Share by Country (2021-2026)
Figure 50. Americas Donafenib Tosylate Sales Market Share by Type (2021-2026)
Figure 51. Americas Donafenib Tosylate Sales Market Share by Application (2021-2026)
Figure 52. United States Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Donafenib Tosylate Sales Market Share by Region in 2025
Figure 57. APAC Donafenib Tosylate Revenue Market Share by Region (2021-2026)
Figure 58. APAC Donafenib Tosylate Sales Market Share by Type (2021-2026)
Figure 59. APAC Donafenib Tosylate Sales Market Share by Application (2021-2026)
Figure 60. China Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 64. India Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Donafenib Tosylate Sales Market Share by Country in 2025
Figure 68. Europe Donafenib Tosylate Revenue Market Share by Country (2021-2026)
Figure 69. Europe Donafenib Tosylate Sales Market Share by Type (2021-2026)
Figure 70. Europe Donafenib Tosylate Sales Market Share by Application (2021-2026)
Figure 71. Germany Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 72. France Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Donafenib Tosylate Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Donafenib Tosylate Sales Market Share by Type (2021-2026)
Figure 78. Middle East & Africa Donafenib Tosylate Sales Market Share by Application (2021-2026)
Figure 79. Egypt Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Donafenib Tosylate Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Donafenib Tosylate in 2026
Figure 85. Manufacturing Process Analysis of Donafenib Tosylate
Figure 86. Industry Chain Structure of Donafenib Tosylate
Figure 87. Channels of Distribution
Figure 88. Global Donafenib Tosylate Sales Market Forecast by Region (2027-2032)
Figure 89. Global Donafenib Tosylate Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Donafenib Tosylate Sales Market Share Forecast by Type (2027-2032)
Figure 91. Global Donafenib Tosylate Revenue Market Share Forecast by Type (2027-2032)
Figure 92. Global Donafenib Tosylate Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Donafenib Tosylate Revenue Market Share Forecast by Application (2027-2032)
